MX2019000428A - Agentes y metodos para la prevencion o el tratamiento de infecciones por h. pylori. - Google Patents
Agentes y metodos para la prevencion o el tratamiento de infecciones por h. pylori.Info
- Publication number
- MX2019000428A MX2019000428A MX2019000428A MX2019000428A MX2019000428A MX 2019000428 A MX2019000428 A MX 2019000428A MX 2019000428 A MX2019000428 A MX 2019000428A MX 2019000428 A MX2019000428 A MX 2019000428A MX 2019000428 A MX2019000428 A MX 2019000428A
- Authority
- MX
- Mexico
- Prior art keywords
- prevention
- agents
- treatment
- methods
- pylori
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Gram-negative bacteria
- C07K16/121—Helicobacter (G); Campylobacter (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/062—Gastritis or peptic ulcer disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16180430.7A EP3272354A1 (en) | 2016-07-20 | 2016-07-20 | Agents and methods for the prevention or treatment of h. pylori infections |
| PCT/EP2017/068297 WO2018015468A1 (en) | 2016-07-20 | 2017-07-20 | Agents and methods for the prevention or treatment of h. pylori infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019000428A true MX2019000428A (es) | 2019-06-10 |
Family
ID=56511365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000428A MX2019000428A (es) | 2016-07-20 | 2017-07-20 | Agentes y metodos para la prevencion o el tratamiento de infecciones por h. pylori. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11471532B2 (https=) |
| EP (2) | EP3272354A1 (https=) |
| JP (1) | JP7189124B2 (https=) |
| CN (1) | CN109715188A (https=) |
| AU (1) | AU2017300021B2 (https=) |
| CA (1) | CA3030787A1 (https=) |
| MX (1) | MX2019000428A (https=) |
| WO (1) | WO2018015468A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3272354A1 (en) | 2016-07-20 | 2018-01-24 | Technische Universität München | Agents and methods for the prevention or treatment of h. pylori infections |
| US11150237B2 (en) | 2018-03-30 | 2021-10-19 | The Regents Of The University Of California | Patient-specific biomarkers of Escherichia coli invasion in inflammatory bowel disease |
| CN108794585A (zh) * | 2018-05-28 | 2018-11-13 | 广东工业大学 | 一种抗幽门螺杆菌的卵黄抗体制备方法及应用 |
| KR102370176B1 (ko) * | 2020-03-02 | 2022-03-03 | 한국생명공학연구원 | HopQ를 포함하는 암전이 억제용 조성물 |
| EP3909601A1 (en) * | 2020-05-11 | 2021-11-17 | LeukoCom GmbH | A novel antibody binding specifically to human ceacam1/3/5 and use thereof |
| CN111675750B (zh) * | 2020-06-11 | 2022-08-30 | 中国药科大学 | 针对癌胚抗原相关黏附分子ceacam的肿瘤靶向肽及其应用 |
| CN112322693A (zh) * | 2020-11-24 | 2021-02-05 | 上海健康医学院 | 一种巨噬细胞中幽门螺丝杆菌的标记方法 |
| CN113388616B (zh) * | 2021-07-27 | 2022-04-26 | 中国海洋大学 | 特异性结合幽门螺旋杆菌的核酸适配体、生物元件、生物传感器及检测方法 |
| CN118480136B (zh) * | 2024-06-19 | 2025-01-14 | 南京澄实生物医药科技有限公司 | 一种预防和治疗金黄色葡萄球菌感染的免疫原性组合物 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR003125A1 (es) | 1995-06-01 | 1998-07-08 | Astra Ab | Antigenos bacterianos para el diagnostico de infecciones con helicobacter pylori, una molecula de adn que lo codifica, un vector, una celula huesped,procedimiento para producir el polipeptido, composiciones para vacunas adecuadas para uso terapeutico y profilactico, el uso del polipeptido en la |
| US20050063987A1 (en) | 1996-07-26 | 2005-03-24 | Chiron Behring Gmbh & Co | Proteins, in particular membrane proteins, of Helicobacter pylori, their preparation and use |
| US20020151462A1 (en) | 1998-02-19 | 2002-10-17 | Ling Lissolo | Helicobacter pylori membrane proteins |
| SE9801287D0 (sv) | 1998-04-14 | 1998-04-14 | Astra Ab | Incorporation of active substances in carrier matrixes |
| SE9801288D0 (sv) | 1998-04-14 | 1998-04-14 | Astra Ab | Vaccine delivery system and metod of production |
| NZ509127A (en) * | 1998-06-19 | 2004-01-30 | Merieux Oravax | Use of LT (E. coli) and CT (cholera toxin) for inducing immune responses against helicobacter infection |
| WO2001083531A1 (en) | 2000-04-27 | 2001-11-08 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for identifying helicobacter antigens |
| GB0010371D0 (en) | 2000-04-29 | 2000-06-14 | Astrazeneca Ab | Helicobacter pylori antigens |
| EP1301204A1 (en) | 2000-07-05 | 2003-04-16 | Merieux OraVax SNC | Immunological combinations for prophylaxis and therapy of helicobacter pylori infection |
| DE10032538A1 (de) | 2000-07-05 | 2002-01-17 | Max Planck Gesellschaft | Vakzine gegen Helicobacter pylori |
| WO2002066501A2 (en) | 2001-01-02 | 2002-08-29 | Hybrigenics | PROTEIN-PROTEIN INTERACTIONS IN $i(HELICOBACTER PYLORI) |
| JP2005506322A (ja) | 2001-08-31 | 2005-03-03 | カイロン ソチエタ ア レスポンサビリタ リミタータ | Helicobacterpyloriワクチン接種 |
| JP3823268B2 (ja) | 2002-05-30 | 2006-09-20 | 独立行政法人科学技術振興機構 | ヘリコバクター・ピロリの細胞死誘導剤 |
| EP1599164B1 (en) | 2003-02-03 | 2015-04-08 | Cerebus Biologicals, Inc. | Methods for treating, preventing and detecting helicobacter infection |
| EP1622933A2 (en) | 2003-04-22 | 2006-02-08 | Intercell AG | H. pylori antigens |
| US20070042448A1 (en) | 2005-06-02 | 2007-02-22 | Institute Pasteur | Use of enzymes from Helicobacter pylori as therapeutical targets |
| CN100460013C (zh) | 2006-09-05 | 2009-02-11 | 重庆康卫生物科技有限公司 | 口服重组幽门螺杆菌疫苗及其制备方法 |
| EP1913955A1 (en) | 2006-10-19 | 2008-04-23 | Gerhard, Markus | Novel method for treating H.pylori infections |
| SI22889A (sl) | 2008-10-28 | 2010-04-30 | Kemijski inštitut | Himerni flagelini za cepiva |
| WO2011018779A1 (en) | 2009-08-13 | 2011-02-17 | The Provost, Fellows and Scholars of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | Modified helicobacter protein |
| WO2011081598A1 (en) | 2009-12-28 | 2011-07-07 | Mivac Development Aktiebolag | New antigens for use in a vaccine against h.pylori infection |
| CN101955545B (zh) | 2010-09-07 | 2012-07-04 | 四川万可泰生物技术有限责任公司 | 一种多靶点重组基因及其蛋白在防治幽门螺旋杆菌感染中的应用 |
| EP2844301A2 (en) | 2012-05-04 | 2015-03-11 | Ineb-instituto de Engenharia Biomédica | Microspheres for treating helicobacter pylori infections |
| EP3272354A1 (en) | 2016-07-20 | 2018-01-24 | Technische Universität München | Agents and methods for the prevention or treatment of h. pylori infections |
-
2016
- 2016-07-20 EP EP16180430.7A patent/EP3272354A1/en not_active Withdrawn
-
2017
- 2017-07-20 EP EP17749134.7A patent/EP3487517B1/en active Active
- 2017-07-20 WO PCT/EP2017/068297 patent/WO2018015468A1/en not_active Ceased
- 2017-07-20 CA CA3030787A patent/CA3030787A1/en active Pending
- 2017-07-20 JP JP2019502575A patent/JP7189124B2/ja active Active
- 2017-07-20 AU AU2017300021A patent/AU2017300021B2/en active Active
- 2017-07-20 MX MX2019000428A patent/MX2019000428A/es unknown
- 2017-07-20 US US16/317,753 patent/US11471532B2/en active Active
- 2017-07-20 CN CN201780045021.7A patent/CN109715188A/zh active Pending
-
2022
- 2022-09-21 US US17/934,113 patent/US12558425B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017300021B2 (en) | 2024-04-11 |
| JP7189124B2 (ja) | 2022-12-13 |
| US20210008207A1 (en) | 2021-01-14 |
| US20230087805A1 (en) | 2023-03-23 |
| JP2019529346A (ja) | 2019-10-17 |
| AU2017300021A1 (en) | 2019-01-24 |
| EP3487517A1 (en) | 2019-05-29 |
| EP3487517B1 (en) | 2023-04-05 |
| WO2018015468A1 (en) | 2018-01-25 |
| CA3030787A1 (en) | 2018-01-25 |
| CN109715188A (zh) | 2019-05-03 |
| US11471532B2 (en) | 2022-10-18 |
| US12558425B2 (en) | 2026-02-24 |
| EP3272354A1 (en) | 2018-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019000428A (es) | Agentes y metodos para la prevencion o el tratamiento de infecciones por h. pylori. | |
| DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
| CL2018002012A1 (es) | Derivados de maitansinoide, conjugados de los mismos y métodos de uso. | |
| JOP20170170B1 (ar) | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق | |
| CL2019000061A1 (es) | Anticuerpo para anti-claudin 18a2 y su utilización. | |
| CL2018001512A1 (es) | Anticuerpos anti-cd73 humanizados. | |
| ECSP18094857A (es) | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo | |
| CO2017000300A2 (es) | Moléculas con especificidad para cd45 y cd79 | |
| CO2018010458A2 (es) | Composiciones y anticuerpos anti-tim-3 | |
| PE20210452A1 (es) | Inhibidores de la arginasa | |
| MX2018003353A (es) | Terapias con celulas cart con una eficacia mejorada. | |
| MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
| UY37230A (es) | Moduladores de la vía de estrés integrada | |
| BR112019012342A2 (pt) | anticorpos il-11 | |
| UY37231A (es) | Moduladores de la vía de estrés integrada | |
| CR20160257A (es) | Anticuerpos e inmunoconjugados anti-cd33 | |
| CL2018001722A1 (es) | Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506) | |
| UY37228A (es) | Moduladores de la vía de estrés integrada | |
| UY37635A (es) | Anticuerpos anti phf-tau y sus usos | |
| MX2016014247A (es) | Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7). | |
| CO2017004932A2 (es) | Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva | |
| CR20180605A (es) | Anticuerpos anti-cd40 y sus usos | |
| MX2016006726A (es) | Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer. | |
| UY37229A (es) | Moduladores de la vía de estrés integrada | |
| CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso |